Preprints & unpublished studies

Brezis M. Neuropsychiatric reactions to finasteride: nocebo or true effect? Authorea. 2022 Aug 10. doi:10.22541/au.166012115.57216742/v1

Flynn R. Suicide and suicidality after exposure to finasteride [study in progress]. Research centre: European Medicines Agency, The Netherlands. Start date: January 2020.

Fusaroli M, Simonsen A, Borrie SA, et al. Identifying medications underlying communication atypicalities in psychotic and affective disorders: a pharmacovigilance study within the FDA Adverse Event Reporting System. medRxiv. Published online 2022. doi:10.1101/2022.09.05.22279609

Green A. Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden (MK-0906-162) [results in Documents tab]. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, European Medicines Agency. Final report: May 2, 2018.

Montaigne M. A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy. OSF. 2022 Feb 11. doi:10.31219/